The advance of bacterididal drugs in the treatment of infection

被引:37
作者
Jeffrey Alder
Barry Eisenstein
机构
[1] Cubist Pharmaceuticals,
关键词
Minimum Inhibitory Concentration; Vancomycin; Endocarditis; Infective Endocarditis; Linezolid;
D O I
10.1007/s11908-004-0042-1
中图分类号
学科分类号
摘要
引用
收藏
页码:251 / 253
页数:2
相关论文
共 47 条
[1]  
Levison ME(1995)Pharmacodynamics of antimicrobial agents. Bactericidal and postantibiotic effects Infect Dis Clin North Am 9 483-495
[2]  
Hooper DC(2001)Mechanisms of action of antimicrobials: focus on fluoroquinolones Clin Infect Dis 32 S9-S15
[3]  
Tally FP(2000)Development of daptomycin for grampositive infections J Antimicrob Chemother 46 523-526
[4]  
DeBruin MF(2001)Oxazolidinone antibiotics Lancet 358 1975-1982
[5]  
Diekema DJ(1988)Mechanism of action of spiramycin and other macrolides J Antimicrob Chemother 22 13-23
[6]  
Jones RN(1999)The tetracyclines Mayo Clin Proc 74 727-729
[7]  
Brisson-Noel A(2000)Mechanism of the antimicrobial drug trimethoprim revisited FASEB J 14 2519-2524
[8]  
Trieu-Cuot P(2002)In vitro bactericidal activity of daptomycin against staphylococci J Antimicrob Chemother 49 467-470
[9]  
Courvalin P(2001)Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams Int J Antimicrob Agents 18 43-48
[10]  
Smilack JD(2003)In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus Antimicrob Agents Chemother 47 1604-1613